Dr. Fischer joined Jennerex in June 2012 as president and chief executive officer, and as a member of the board of directors. He brings 20 years of drug development and commercialization experience in the biopharmaceutical industry to Jennerex, serving most recently as co-founder, president and CEO of Ocera Therapeutics, where he led the approval of Zysa®, the first treatment ever approved for Irritable Bowel Syndrome in Europe and developed the first ammonia scavenger for the treatment of complications of liver disease . Dr. Fischer has been involved in and managed four healthcare companies and held senior management positions at DuPont-Merck, DuPont Pharmaceuticals, and Hoffmann-La Roche in oncology, virology and liver disease. Dr. Fischer was responsible for the launch of Invirase®, the first protease inhibitor, in the U.S and led the global launch of Sustiva® the first once-daily anti-HIV now part of the fixed dose combination therapy Atripla®. Dr. Fischer is the chairman of the board of directors of Tobira Therapeutics, vice-chairman of Ocera Therapeutics and received his undergraduate degree from the University of Geneva and his medical degree from the Geneva Medical School, Switzerland.
Dr. Bell is internationally-renowned for his leading-edge research using oncolytic viruses to treat cancer. In addition to his leadership role at Jennerex, he is the director of the Ontario Institute for Cancer Research in Biotherapeutics, a program comprised of scientists and clinicians across Ontario whose common objective is to develop viral and immunotherapeutics that improve the quality and length of cancer patients lives. He formed, and continues to lead, the Canadian Oncolytic Virus Consortium, a peer-reviewed, multi-disciplinary group developing virus-based cancer therapeutics. He serves as a senior scientist at the Ottawa Health Research Institute (OHRI), a research institution affiliated with the University of Ottawa and the research arm of The Ottawa Hospital. Prior to his tenure at Jennerex and OHRI, Dr. Bell was a senior scientist at the National Cancer Institute of Canada after launching his independent research career in the biochemistry department of McGill University. Dr. Bell serves on the board of directors for the Canadian Cancer Society and is an executive member of the National Cancer Institute of Canada Clinical Trials Group. His research program has been continuously funded by peer-reviewed grants for over 20 years and he has authored over 90 publications and presentations. He completed his post-doctoral studies at the Medical Research Council in London, England and received his PhD in virology and immunology at McMaster University in Ontario, Canada.
Ms. Longpre joined the Company in April 2008 as a clinical consultant and became chief operating officer in June 2010. She has over 19 years of drug development and operations experience in leadership and senior roles in biotechnology and contract research organizations (CROs). She has wide-ranging experience in strategic planning, project management and all phases of clinical development including direct management of several global pivotal trials. Prior to Jennerex, she was senior vice-president, clinical and corporate development at MedGenesis Therapeutix. Ms. Longpre has also held senior management positions of increasing responsibility at PRA International, a global CRO, including vice president of proposals and contracts, vice president of quality and process management, director of global regulatory affairs, and director of operations during which time she was responsible for global clinical programs in several therapeutic areas. Ms. Longpre holds an MSc in medical science from Harvard Medical School, an MBA from Queens University Executive Program, and a BA from Cornell University.
Mr. Schafer has more than 20 years of broad functional and strategic leadership as well as senior management expertise including more than 10 years as a chief financial officer (CFO) of public companies in the biopharmaceutical industry. Prior to Jennerex, he served as the CFO of Onyx Pharmaceuticals (approximately $2 billion market capitalization during his tenure) and served as CFO of Cerus Corporation prior to that. While at public biotechnology organizations, he successfully raised over $600 million in capital through a variety of financial instruments, including public offerings, private investment in public equities (PIPEs), equity line and strategic loan facilities. He brings relevant financial knowledge for companies in all stages of drug development including asset acquisition, preclinical development, clinical development and commercialization, and has been an integral member of corporate development review teams. Mr. Schafer serves on the board of directors for Nile Therapeutics. He received his MBA from the Anderson Graduate School of Management at the University of California, Los Angeles and his BSE in mechanical engineering from the University of Pennsylvania.
Mr. Peetz joined Jennerex in April 2012 as Vice President, Corporate Development. Prior to Jennerex, Mr. Peetz held positions of increasing responsibility at Onyx Pharmaceuticals in the areas of corporate development & strategy, marketing and finance. At Onyx, Mr. Peetz led Strategic Planning and was responsible for corporate strategy, portfolio review and product lifecycle management. Mr. Peetz's commercial experience at Onyx included marketing and commercial planning roles on Nexavar, Regorafenib and Kyprolis. Prior to his strategy and commercial work, he led Financial Planning and Analysis, leading corporate planning, budgeting, and analytics and supporting due diligence and financings. Prior to Onyx, Mr. Peetz provided corporate advisory and merger and acquisition support at LaSalle Corporate Finance, a part of ABN AMRO. Mr. Peetz has also held positions at Abgenix and Solazyme. Mr. Peetz holds an MBA from Stanford Graduate School of Business and graduated summa cum laude from Washington University in St. Louis.
Dr. Fritsch has more than 20 years of biopharmaceutical regulatory and quality affairs experience. Prior to Jennerex, she served as vice president of global regulatory affairs and compliance for Anthera Pharmaceuticals, where she was responsible for the strategy and implementation of all U.S. and international regulatory activities for the company's late-stage product portfolio. Previously‚ Dr. Fritsch served as senior director of regulatory affairs at Peninsula Pharmaceuticals‚ where she oversaw the late-stage regulatory strategy and operations for two key compounds, spearheading all regulatory filings including Investigational New Drug (IND) applications, fast-track designation and orphan drug applications. Prior to Peninsula, she served as the head of regulatory affairs at Onyx Pharmaceuticals, providing global leadership for the development of Nexavar® for its original gene therapy program. In addition‚ Dr. Fritsch held various management positions and oversaw several New Drug Application (NDA) approvals at Genentech‚ Inc. and Oclassen Pharmaceuticals. In addition to her tenure in biotechnology companies, Dr. Fritsch also acted as President of East Bay Bio‚ Inc.‚ a regulatory consulting company focusing on strategic drug development and submission work in all phases of development from pre–IND to NDA filing and post approval/marketing issues. Dr. Fritsch received her Doctor of Pharmacy degree from Creighton University and her BA from the University of Nebraska.
Dr. Burke has approximately 20 years of experience in basic and applied clinical science of genetic and immunotherapy. Prior to Jennerex, Dr. Burke was the Director of Cancer Research at Billings Clinic, where he was also a clinical investigator for JX-594. His clinical research using immunotherapeutics including oncolytic viruses for the treatment of various cancers have advanced the understanding of the medical applications for oncolytic virus therapy. He had previously served as associate director of clinical research at Cell Genesys, Inc., where he was responsible for the development of the oncolytic adenovirus platform of agents and other gene therapy vaccines for the treatment of cancer and other diseases. In addition, after completing his Hematology and Oncology Fellowship at UC San Francisco (UCSF), he was an attending physician at UCSF in the department of hematology and oncology. He received his M.D. from Georgetown University and his B.S. in biochemistry and cell biology from the University of California, San Diego. He is the author of more than 10 key publications and presentations detailing the use of gene therapy and oncolytic viruses to treat cancer. He is board certified in hematology, oncology and internal medicine.
Dr. Roth has over 20 years of experience in the biopharmaceutical industry. He is the founder of Roth Bioprocessing Consulting (RBC), an international consulting firm advising clients on all aspects of product development and manufacturing. RBC has worked with clients in the US, EU and China and is also a member of a German consultants network group.
Prior to the founding of RBC Dr. Roth was director of Technical Affairs at Dynavax Technologies, responsible for process development and manufacturing of protein therapeutics and vaccines.
Previously Dr. Roth worked in positions of increasing responsibility at Berlex Laboratories on the development of mammalian, microbial and gene therapy products. Dr. Roth started his career in Germany with Schering AG, an international pharmaceutical company recently acquired by Bayer AG.
Dr. Roth holds a Ph.D. and a masters degree in chemical engineering from Technical University Berlin, Germany.
Dr. Moon has over 15 years of experience in oncology drug development and is a founding team member of Jennerex, overseeing development sciences including clinical bioanalytics, preclinical development and next-generation research. Prior to Jennerex, she was part of the start-up team at Cytokinetics, establishing the cell-based screening program and managing intellectual property filings on the high-content screening platform. At Onyx Pharmaceuticals, she served as project manager of the oncolytic virus program and worked on scientific projects within the small molecule therapeutics partnership with Bayer. She received her Ph.D. in Molecular & Cell Biology from the University of California, Berkeley and an AB in Biology from Harvard University.
Dr. Hwang has over 20 years of experience in the field cancer research, with more than 10 years focused specifically on cancer virotherapy. Prior to Jennerex, he was head of clinical pharmacology at Pusan National University in South Korea and vice president of research for liver and cholangio carcinomas at YangSan Hospital. During his tenure at Pusan National University, he gained practical and clinical knowledge of liver cancer patients and different treatment regimens available. In addition, Dr. Hwang served as a professor at Baylor School of Medicine and Dong-A University School of Medicine in South Korea. Dr. Hwang serves on the board of directors for SillaJen BT Inc. He has authored more than 50 publications in the field of cancer. He was a post-doctoral fellow at Johns Hopkins University and received both his DDS and PhD in physiology from Pusan National University in South Korea.